echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hausen Pharmaceutical's Class 1 new drug was approved to be marketed for the treatment of chronic hepatitis B

    Hausen Pharmaceutical's Class 1 new drug was approved to be marketed for the treatment of chronic hepatitis B

    • Last Update: 2021-08-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of June 22, China’s National Food and Drug Administration (NMPA) recently announced that Haosen Pharmaceutical’s Class 1 new drug imitenofovir tablets (also known as eimofolamine tenofovir tablets) has officially been approved in China.


    According NMPA Center for Drug Evaluation (CDE) priority reviews publicity, presumably for the application of indications: for the treatment of adult patients with chronic hepatitis


    Screenshot source: NMPA official website

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.